Table 5.
Effect of Hashimoto's disease on growth factor levels: FGF: fibroblast growth factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; M-CSF: macrophage colony-stimulating factor; PDGF-BB: platelet-derived growth factor–BB; VEGF: vascular endothelial growth factor.
| Saliva | Plasma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control group | Study group | p value | Control group | Study group | p value | |||||
| Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | Mean ± SD | Median (min-max) | |||
| G-CSF | 493.9 ± 72.24 | 497 (363.1-649.2) | 574.1 ± 115.8 | 587.8 (344.1-894.8) | 0.0066 | 603.7 ± 91.3 | 590.2 (454.4-764.7) | 777.1 ± 164 | 726.8 (455.9-1162) | <0.0001 |
| VEGF | 1443 ± 850.1 | 1221 (53.24-3643) | 2631 ± 1480 | 2433 (634.8-6122) | 0.0025 | 191.1 ± 64.73 | 179.4 (91.19-331) | 271.3 ± 158.2 | 252.3 (24.03-608.9) | 0.0842 |
| TRIAL | 519.3 ± 307.7 | 441.3 (16.85-1154) | 1009 ± 1011 | 727.1 (24.71-4653) | 0.0472 | 80.32 ± 30.77 | 78.42 (26.96-143.5) | 101.6 ± 47.97 | 101.7 (12.02-191.1) | 0.0878 |
| FGF | 5.371 ± 1.205 | 5.412 (3.418-8.347) | 5.737 ± 1.197 | 5.54 (3.717-8.09) | 0.3571 | 34.45 ± 7.104 | 33.35 (19.34-46.92) | 33.85 ± 9.314 | 31.99 (17.48-54.19) | 0.6443 |
| GM-CSF | 24.12 ± 6.793 | 22.65 (11.77–37.98) | 25.6 ± 10.25 | 25.17 (5.405 –50.55) | 0.5637 | 98.28 ± 15.9 | 100.2 (70.8-140.6) | 102.9 ± 26.21 | 103.9 (48.13-146.8) | 0.4762 |
| M-CSF | 228.5 ± 137.5 | 206 (13.03-582.5) | 309.7 ± 268.6 | 238 (18.8-1301) | 0.2182 | 65.97 ± 30.89 | 69.24 (4.661-135.7) | 85.52 ± 34.76 | 98.87 (5.619-131.4) | 0.0223 |
| PDGF-BB | 480.9 ± 165.9 | 490 (103.6-740) | 534 ± 262.3 | 548.2 (111-1060) | 0.5096 | 1041 ± 337.1 | 1092 (351.6-1689) | 976.5 ± 552 | 1095 (39.4-2135) | 0.6305 |